Used in the treatment of B-cell non-Hodgkin's lymphoma and chronic lymphocytic leukemia by targeting CD20 antigens on B-cells, leading to their depletion through mechanisms like antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Also utilized as a reference standard in biosimilar development and analytical testing for consistency and efficacy comparison with other anti-CD20 antibodies.